Handbook of Experimental Pharmacology

Safety and Tolerability of SGLT2 Inhibitors

By Marcel H.A. Muskiet, Daniël H. van Raalte, Mark M. Smits

ReviewInterventions

The paper

Marcel H.A. Muskiet, Daniël H. van Raalte, Mark M. Smits

Leiden University Medical Center; Radboud University Medical Center

Handbook of Experimental Pharmacology, 13 Aug 2026

doi.org/10.1007/164_2026_826 PubMed 42587086

Clinical Pharmacology and Therapeutics4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk
The American Journal of Cardiology8 Oct 2026
Drug class linked to fewer deaths or complications in kidney disease
Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
medRxiv4 Oct 2026
NMR metabolomics improves prediction of cardiometabolic diseases